Cetuximab

  • Favorite
Inorbvict Healthcare India Pvt Limited

Business Type:Manufacturer

Country/Region:India

Ddu Verified

HOT Rank

6/10

Product Information

  • Pharmacopeia:CP
  • Shelf Life:18 months
  • Storage:Sealed

Description

Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer


A diagnostic immunohistochemistry assay (EGFR pharmDx) can be used to detect EGFR expression in the tumor material. Approximately 75% of patients with metastatic colorectal cancer have an EGFR-expressing tumor and are therefore considered eligible for treatment with cetuximab or panitumumab, according to FDA guidelines. Unfortunately, there is evidence that immunohistochemical EGFR receptor testing does not predict response to either cetuximab or panitumumab, so that this has been called a "misleading biomarker" that has nevertheless caused insurers and even health systems to deny payment for EGFR antibody treatment for patients who lack a positive tumor EGFR histochemical test

You Might Also Like
Change a group
Inquiry Cart(0)